PubRank

William F Owen

Author PubWeight™ 44.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
2 Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002 2.98
3 A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004 2.29
4 Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002 1.92
5 Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002 1.83
6 Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 2002 1.82
7 National profile of practice patterns for hemodialysis vascular access in the United States. J Am Soc Nephrol 2002 1.79
8 A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol 2003 1.78
9 Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005 1.54
10 Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003 1.42
11 Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005 1.37
12 Does calcium kill ESRD patients--the skeptic's perspective. Nephrol Dial Transplant 2002 1.37
13 Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients. Nephrol Dial Transplant 2003 1.31
14 Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis 2006 1.28
15 Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials 2009 1.13
16 White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003 1.12
17 Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004 1.08
18 Relationship between nephrologist care and progression of chronic kidney disease. N C Med J 2007 1.08
19 The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003 1.05
20 Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002 1.03
21 Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: process, outcomes, and implications. Am J Kidney Dis 2003 0.83
22 Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J 2004 0.80
23 Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003 0.79
24 Preparing the patient for renal replacement therapy. Teamwork optimizes outcomes. Postgrad Med 2002 0.79
25 Perception versus reality of the burden of chronic kidney disease in the United States. J Am Soc Nephrol 2002 0.77
26 Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004 0.75
27 Inequality in quality: are patient health activation and CQI corrective approaches? J Am Soc Nephrol 2004 0.75
28 Does time of day of hemodialysis affect survival? JAMA 2002 0.75
29 Perspectives on humanism in medicine from the 2012 Edward J. III Excellence in Medicine honorees. MD Advis 2012 0.75
30 Key concepts in biostatistics: using statistics to answer the question "is there a difference?". Semin Dial 2002 0.75
31 Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? Nephrol Dial Transplant 2003 0.75
32 Toward a continuous quality improvement paradigm for hemodialysis providers with preliminary suggestions for clinical practice monitoring and measurement. Hemodial Int 2003 0.75
33 Comparison of mortality and intermediate outcomes between medicare dialysis patients in HMO and fee for service. Am J Kidney Dis 2002 0.75
34 Study designs and their potential influence on conclusions. Semin Dial 2002 0.75
35 Beta 2-microglobulin amyloidosis: role of monocytes/macrophages. Curr Opin Nephrol Hypertens 2002 0.75
36 An introduction to epidemiology and biostatistics and issues in interpretation of studies. Semin Dial 2002 0.75